Sign in Subscribe
Radiation (Physics)

Radiation Therapy Shows Significant Survival Benefits in Advanced-Stage ENKTCL Patients

Strategic Insights

— 1 min read

Research from Peking Union Medical College Hospital has found that adding radiation therapy (RT) to asparaginase-based chemotherapy (CT) in patients with advanced-stage extranodal NK/T-cell lymphoma (ENKTCL) provides significant survival benefits. The study, which included 170 patients, found that patients who received CT followed by RT had a better overall survival (OS) and progression-free survival (PFS) compared to those who received CT alone. The results suggest that RT may be a crucial component in the treatment of advanced-stage ENKTCL.

Key Takeaways:

  • The study included 170 patients with advanced-stage ENKTCL who received asparaginase-based CT.
  • Patients were divided into two groups: those who received CT alone (105 patients) and those who received CT followed by RT (65 patients).
  • The results showed that patients who received CT followed by RT had a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to those who received CT alone.
  • The addition of RT to ASP-based CT provided significant survival benefits in all patients and chemoresponsive patients with advanced-stage ENKTCL.
  • The study used the Kaplan-Meier method to estimate OS and PFS, and compared the two groups using the log-rank test.
  • Univariable Cox regression analysis was performed to identify potential factors associated with OS and PFS.

Statistics:

  • 170 patients with advanced-stage ENKTCL were included in the study.
  • 105 patients received CT alone, while 65 patients received CT followed by RT.
  • The number of patients who received additional RT was 58, while 54 patients did not receive RT.
  • The overall survival (OS) and progression-free survival (PFS) rates were estimated using the Kaplan-Meier method.
  • The numbers of patients achieving complete response (CR) and partial response (PR) after CT were 112, with 58 patients receiving additional RT and 54 patients not receiving RT.

Sources:

  • Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group Database. International Journal of Radiation Oncology*Biology*Physics, 2025.
  • Xiao-Rong Hou, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, People's Republic of China.
  • International Journal of Radiation Oncology*Biology*Physics can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

Read more